- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03358329
Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)
November 26, 2019 updated by: Intersect ENT
The ENCORE Study: Safety Evaluation of Repeat Placement of the Corticosteroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps
The ENCORE Study is designed to evaluate the repeat administration of the S8 Sinus Implant in chronic sinusitis (CS) patients with recurrent nasal polyps.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The ENCORE Study is a prospective open-label, non-randomized, multicenter study in CS patients who had undergone prior endoscopic sinus surgery (ESS) including bilateral total ethmoidectomy and present with bilateral ethmoid polyposis.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Sacramento, California, United States, 95815
- Sacramento ENT
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University School of Medicine
-
-
Illinois
-
Naperville, Illinois, United States, 60540
- DuPage Medical Group
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Advanced ENT & Allergy
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- Associated Surgical Specialists
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- BreatheAmerica of Albuquerque
-
-
New York
-
New York, New York, United States, 10016
- Madison ENT
-
-
North Carolina
-
Concord, North Carolina, United States, 29025
- Charlotte Eye, Ear, Nose and Throat Associates
-
-
Utah
-
North Logan, Utah, United States, 84341
- Bridgerland Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient has provided written informed consent using a form approved by the reviewing institutional review board (IRB) and sponsor.
- Patient is ≥ 18 years of age.
- Patient is willing and able to comply with protocol requirements.
- Patient has a confirmed diagnosis of CS with nasal polyps, as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".
- Patient has undergone prior ESS including bilateral total ethmoidectomy at least 90 days prior to screening.
- Patient has evidence of bilateral ethmoid sinus obstruction due to polyposis warranting intervention (polyp grade ≥ 2 on each side).
- Patient is able to tolerate daily use of Mometasone Furoate Nasal Spray (MFNS).
- Patient is able to tolerate topical/local anesthesia.
- In the opinion of the investigator, patient's ethmoid sinus anatomy is amenable to in-office bilateral placement of the S8 Sinus Implant (i.e., able to pass into the middle meatus on both sides the S8 Sinus Implant with 20 mm in nominal length and 7 mm in compressed diameter).
- Female patients of reproductive potential must not be pregnant or nursing and must agree to not become pregnant during their participation in the study.
- Female patients of childbearing potential must agree to use consistent and acceptable method(s) of birth control during their participation in the study.
Exclusion Criteria:
- Patient has extensive ethmoid sinus polyp grade (grade 4 on at least one side).
- Patient has extensive adhesions/synechiae (grade 3 or 4).
- Patient has used parenteral and injected steroids (e.g., Kenalog injection) during 30 days prior to the baseline procedure.
- Patient has used oral steroids, budesonide or other sinus steroid irrigations/rinses, nebulized steroids administered nasally or budesonide drops during 14 days prior to the baseline procedure.
- Patient has oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or asthma.
- Patient has known history of allergy or intolerance to corticosteroids or mometasone furoate.
- Patient has used monoclonal antibodies for asthma, allergies or nasal polyps (e.g., Dupixent, Nucala, Xolair) during 30 days prior to the baseline procedure.
- Patient requires monoclonal antibodies for asthma, allergies or nasal polyps during the duration of the study.
- Patient has presence of physical obstruction that would preclude access and placement of the S8 Sinus Implant in the middle meatus (e.g., severe septal deviation, septal spur, very small middle meatus, total obstruction of the sinonasal passage with severe adhesion, scarring, polypoid edema or polyps).
- Patient has known history of human immunodeficiency virus (HIV) or immunoglobulin G or A subclass deficiency.
- Patient has clinical evidence of acute sinusitis (AS), as defined in the 2016 "International Consensus Statement on Allergy and Rhinology".
- Patient has clinical evidence or suspicion of invasive fungal sinusitis (e.g., bone erosion on prior computed tomography (CT) scan, necrotic sinus tissue).
- Patient has evidence of severe concomitant disease or condition expected to compromise survival or ability to complete assessments during the 365-day study follow-up period (e.g., cancer).
- Patient is currently participating in another clinical study.
- Patient has previously undergone ESS and experienced a cerebrospinal fluid (CSF) leak or has residual compromised vision as a result of a complication in a prior ESS procedure.
- Patient has known dehiscence of the lamina papyracea.
- Patient has evidence of active tuberculosis or active viral illness (e.g., ocular herpes simplex, chickenpox, measles).
- Patient has known history or diagnosis of glaucoma or ocular hypertension (prior ocular exam with intraocular pressure of >21 mmHg and pressure lowering medication given) or posterior subcapsular cataract.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: S8 Sinus Implant
corticosteroid-eluting sinus implant containing 1350 mcg of mometasone furoate (MF)
|
In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Implant-Related Serious Adverse Events
Time Frame: 365 days
|
Evaluated via tabulation of implant-related serious adverse events (SAE) reported by subjects between consent and Day 365.
|
365 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SNOT-22 Total Score
Time Frame: Baseline, 90 days, 180 days
|
Sino-Nasal Outcomes Test (SNOT-22) is a validated disease-specific symptom-scoring instrument consisting of 22 questions, each scored on a 6-point scale of 0 (no problem) to 5 (probably as bad as it can be) based on the subject's recollection of symptoms over the past 2 weeks.
The total score ranges from 0 to 110, with a higher score reflecting greater symptom burden.
Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value from baseline.
Negative values for change from baseline indicate reduction (improvement) in sino-nasal symptoms.
|
Baseline, 90 days, 180 days
|
Nasal Obstruction/Congestion Score
Time Frame: Baseline, 90 days, 180 days
|
Determined on a scale of 0 (no symptoms) to 3 (severe symptoms) based on the subject's recollection of symptoms over the past week using a reflective paper questionnaire.
Change from baseline to 90 days and to 180 days is calculated as the value at 90/180 days minus the value at baseline.
Negative values for change from baseline to follow-up indicate reduction (improvement) in nasal obstruction/congestion.
|
Baseline, 90 days, 180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Peter Manes, MD, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 13, 2017
Primary Completion (Actual)
January 17, 2019
Study Completion (Actual)
January 17, 2019
Study Registration Dates
First Submitted
November 27, 2017
First Submitted That Met QC Criteria
November 27, 2017
First Posted (Actual)
November 30, 2017
Study Record Updates
Last Update Posted (Actual)
November 27, 2019
Last Update Submitted That Met QC Criteria
November 26, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P500-0717
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Sinusitis
-
Loma Linda UniversityWithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
LifeBridge HealthUnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - PosteriorUnited States
-
Kaiser PermanenteWithdrawnChronic Sinusitis | Chronic Sinus Infection | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinus CongestionUnited States
-
Collin County Ear Nose & ThroatIntersect ENTCompletedChronic Sinusitis, EthmoidalUnited States
-
Tampere University HospitalRecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis RecurrentFinland
-
STS MedicalNot yet recruitingChronic Sinusitis, Ethmoidal
-
Centre Hospitalier Intercommunal CreteilRecruitingSinusitis, Chronic | Sinus Infection ChronicFrance
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Australia
-
Lyra TherapeuticsCompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)Poland, Australia, New Zealand, Austria, Czechia
-
Lyra TherapeuticsRecruitingChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)United States, Poland, Bulgaria, Belgium, Germany, Hungary
Clinical Trials on S8 Sinus Implant
-
Intersect ENTCompletedChronic SinusitisUnited States
-
Intersect ENTCompletedChronic Sinusitis | Nasal PolyposisUnited States
-
Intersect ENTCompletedChronic Sinusitis | Nasal PolypsUnited States
-
Cairo UniversityUnknown
-
University of Sao PauloCompletedDental Implants | Sinus Floor Augmentation | Platelet-rich Fibrin | Maxillary Sinus | Cone-beam Computed Tomography | Bone Substitutes | Atrophic MaxillaBrazil
-
Cairo UniversityUnknownMaxillary Sinus Lift
-
Studio Odontoiatrico Associato Dr. P. Cicchese...RecruitingEdentulous Alveolar Ridge Atrophy | Edentulous; Alveolar Process, AtrophyItaly
-
Intersect ENTAdvance Research AssociatesCompletedChronic SinusitisUnited States